|
Dr. William Schmidt is currently the head of NorthStar Consulting, LLC, which specializes in providing advice on preclinical and clinical studies of novel analgesic drugs. Dr. Schmidt was previously VP, Clinical Research, for Renovis, Inc., in South San Francisco, CA, an emerging biopharmaceutical company developing drugs to treat stroke, chronic neurological diseases, and pain. Prior to Renovis, Dr. Schmidt was VP, Scientific Affairs, at Adolor Corporation in Exton, PA, where he was a key member of the team leading to the clinical development and NDA filing of Entereg (alvimopan). Dr. Schmidt continues as a Scientific Advisory Consultant to both Adolor and Renovis. Dr. Schmidt is Immediate Past President of the Eastern Pain Association, the largest regional affiliate of the American Pain Society. He has over 25 years of pharmaceutical industry experience with a special emphasis on the discovery and development of novel analgesic and narcotic antagonist drugs. He is the co-editor of Pain: Current Understanding, Emerging, Therapies, and Novel Approaches to Drug Discovery (Marcel Dekker, 2003; 2nd edition in preparation). Dr. Schmidt received his PhD in Pharmacology from the University of California, San Francisco. Following his postdoctoral fellowship at Boston University School of Medicine, Dr. Schmidt joined DuPont Pharmaceuticals (later the DuPont Merck Pharmaceutical Company) where he helped to develop Nubain, Trexan, ReVia and the oxycodone-ibuprofen formulation used in Combunox. | 